Humacyte公司宣布通过对其生物工程血管产品Symvess®在美国以外市场的权利进行战略性重组,进一步拓展全球商业版图与业务发展空间。此次权利调整将优化公司国际资源配置,为未来市场扩张奠定坚实基础。
Humacyte公司宣布通过对其生物工程血管产品Symvess®在美国以外市场的权利进行战略性重组,进一步拓展全球商业版图与业务发展空间。此次权利调整将优化公司国际资源配置,为未来市场扩张奠定坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.